Dr. Sauter on CAR T Cells in Real-World Patients With Hematologic Malignancies
Craig Sauter, MD, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor T-cell therapy.
Craig Sauter, MD, a hematologic oncologist and clinical director of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor (CAR) T-cell therapy.
Patients are often faced with side effects such as severe cytopenia for long periods of time, says Sauter. If patients fail CAR T-cell therapy, further therapy becomes challenging. When patients progress, they must receive cytotoxic therapy with adequate hematopoietic reserve to tolerate the CAR T cells.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
